MétaCan
Menu
Back to cohort
Record W7117293821 · doi:10.1002/alz70858_103458

Efficacy and Safety of Brexpiprazole in Agitation Associated with Dementia in Alzheimer's Disease: A Systematic Review and Meta‐analysis

2025· article· en· W7117293821 on OpenAlexaff
Hammad Javaid, Muhammad Nabeel Saddique, Ayaan Musani, Anurag Jha, Meeram Noor, Mahnoor Arfan, Umaima Cheema, Shamikha Cheema

Bibliographic record

VenueAlzheimer s & Dementia · 2025
Typearticle
Languageen
FieldPsychology
TopicHealthcare Decision-Making and Restraints
Canadian institutionsWilfrid Laurier University
Fundersnot available
KeywordsDementiaCognitionCognitive impairmentPsychomotor agitationQuality (philosophy)DeliriumMEDLINE

Abstract

fetched live from OpenAlex

BACKGROUND: Agitation is one of the most distressing neuropsychiatric symptoms in patients with dementia due to Alzheimer's disease (AD), significantly impacting patients' quality of life and increasing caregiver burden. Current management options for agitation in AD remain limited, with many treatments associated with modest efficacy and considerable safety concerns. Brexpiprazole, a serotonin-dopamine activity modulator, has recently emerged as a potential therapeutic option for this challenging clinical scenario. This systematic review and meta-analysis aim to evaluate the efficacy and safety of brexpiprazole in managing agitation associated with dementia in AD. METHOD: statistics. A p-value of <0.05 was considered statistically significant. All the calculations were performed using RevMan 5.4. RESULT: This meta-analysis included 4 studies involving 1440 patients (944 vs. 496) suffering from agitation associated with dementia in AD. Brexpiprazole demonstrated a significant reduction in the Cohen-Mansfield Agitation Inventory (CMAI) score (MD: -3.94 [95% CI: -6.21 to -1.67], p <0.001) and Neuropsychiatric Inventory-Nursing Home (NPI-NH) score (MD: -0.67 [95% CI: -1.08 to -0.26], p = 0.002) from baseline, with the greatest improvement observed at the 2-3 mg dose. There was statistically significant change in SAS score (MD: 0.38, [95% CI: 0.18 to 0.58], p = 0.0002) but no difference in Mini-Mental State Examination (MMSE) score (MD: -0.26 [95% CI: -0.53 to 0.01], p = 0.06) and Clinical Global Impression-Severity (CGI-S) score (MD: -0.16 [95% CI: -0.34 to 0.01], p = 0.06) from the baseline with brexpiprazole. There was no difference between two groups regarding serious adverse events (p = 0.57), dizziness (p = 0.49), extrapyramidal effects (p = 0.18) and mortality (p = 0.22). CONCLUSION: Brexpiprazole significantly reduces agitation symptoms in Alzheimer's disease, as shown by improvements in CMAI and NPI-NH scores, with no significant cognitive or safety concerns. While promising, limitations include moderate heterogeneity and short follow-up durations. Future studies should focus on long-term effects, quality of life, and identifying optimal patient subgroups for treatment.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.009
metaresearch head score (Gemma)0.018
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: Meta-analysis
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.016
Threshold uncertainty score0.048

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0090.018
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0160.035
Bibliometrics0.0040.005
Science and technology studies0.0010.001
Scholarly communication0.0020.001
Open science0.0020.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.041
GPT teacher head0.361
Teacher spread0.320 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & DementiaSame topicHealthcare Decision-Making and RestraintsFrench-language works237,207